IMMUNOREGULATORY MECHANISMS OF PROGRESSION OF SEASONAL ALLERGIC RHINITIS
Despite numerous studies referring to seasonal allergic rhinitis (SAR), many problems, especially those related to the prognosis of clinical progression, are relevant. To generate ideas about the features of the functioning of the immune system in conditions of progression of the severity of SAR progress, the parameters of the innate and adaptive immune response in patients with mild to moderate severity of the active phase of SAR were studied. 62 people aged 18-50 y.o. who were divided into 2 groups (34 people with mild degree and 28 patients with moderate severity of SAR) were examined in accordance with Federal Clinical Recommendations, taking into account the assessment of severity of clinical symptoms (TNSS) and quality of life (RQLQ). The results of the analysis of the obtained data indicate that the changes in the immune status in patients with SAR of light and moderate severity during the clinical manifestation of allergy are unidirectional and are regulated by the intensification of the maturation processes, the functional features of the T- and B- effectors, the products of oppositely reacting mediators of the pro- and anti-inflammatory directivity in inhibiting readiness T-cells to apoptosis, mechanisms of immunosuppression, adaptive potential of neutrophils, lytic activity of natural killers. Progression of SAR from mild to moderate severity is associated with increased maturation of B cells, weakening of T-regulatory immunosuppression and aggravation of cytokine imbalance.
About the authorsSizyakina Lyudmila Petrovna
Ilina N.I., Kurbacheva O.M., Sizyakina L.P., Ukhanova O.P., Shogenova M.S., Borisin M.Yu. Immunobiological drugs in the treatment of bronchial asthma (Council of Experts). Ros. Allergol. Zhurn. 2015; 5: 90-3. (in Russian)
Palomares O, Crameri R, Rhuner C. The contribution of biotechnology toward progress in diagnosis, management and treatmeant allergic diseases. Allergy. 2014; 69 (2): 1588-601.
Vishneva E.A., Namazova-Baranova L.S., Alekseeva A.A., Efendieva K.E., Levina Yu. G., Tomilova A. Yu., et al. Allergen-specific immunotherapy in children. Standardization of approaches to the assessment of effectiveness. Pediatricheskaya farmacologiya. 2015; 12 (2): 173-9. (in Russian)
Soldatov A.A. Mechanisms of allergic reactions of immediate type, drugs and methods of specific immunotherapy. Immunologiya. 2016; 37 (1): 51-9. (in Russian)
Gushchin I.S. IgE-mediated hypersensitivity as a response to a violation of the barrier function of tissues. Immunologiya. 2015; 36 (1): 45-52. (in Russian)
Sizyakina L.P., Andreeva I.I., Semenova N.I. Features of the immune status of patients with a moderate form of seasonal allergic rhinitis. Ros. Allergol. Zhurn. 2016; 6: 18-22. (in Russian)
Yashina L.A., Ignatyeva V.I. Possibilities of azelastine in the treatment of seasonal allergic rhinitis in the format of the new study MP4001. Astma i allergy. 2013; No. 1: 55-58. (in Russian)
Semenova I.V., Vykhristenko L.R. The quality of life of patients with hay fever with various methods of treatment. Meditsinskie Novosti. 2014; 9: 83-6. (in Russian)
Juniper E.F., Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy. 1991; 21(1):77-83.
Khaitov R.M., Pinegin B.V., Yarilin A.A. Guide to Clinical Immunology. Diagnosis of diseases of the immune system: a guide for doctors. [Rukovodstvo po klinicheskoy immunologii. Diagnostika zabolevaniy immunnoy sistemy: rukovodstvo dlya vrachey]. Moscow: GEOTAR-Media; 2009. (in Russian)
Martynov A.I., Pinegin B.V., Paschenkov M.V. Innate immunity as a system of protection from the impact on the human body of anthropogenic factors. [Vrozhdennyy immunitet kak sistema zashchity ot vozdeystviya na organizm cheloveka antropogennykh faktorov]. Moscow: Mittel Press; 2014. (in Russian)
Ketlinsky S.A., Simbirtsev A.S. Cytokines. [Tsitokiny]. SPb: FOLIO; 2008. (in Russian)
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.